GORMAN KEVIN CHARLES — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

GORMAN KEVIN CHARLES has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $52.60M.

Profile

GORMAN KEVIN CHARLES

Kevin Charles Gorman is a corporate director known for his role at Neurocrine Biosciences Inc, a company focused on neurological and endocrine-related drug development. He has been involved in multiple SEC filings related to his directorship but has not reported any stock transactions.

RoleDirector
Notability30/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-08XNCRXencor IncA — Grant or award10.3K$0.00
2026-06-17XNCRXencor IncS — Open-market sale7.5K$12.31$93K
2026-05-21NBIXNEUROCRINE BIOSCIENCES INCS — Open-market sale245.1K$154.33$37.82M
2026-05-21NBIXNEUROCRINE BIOSCIENCES INCM — Option exercise205.1K$43.24$8.87M
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCF — Tax withholding / forfeiture34.4K$124.12$4.27M
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCA — Grant or award63.7K$0.00
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCF — Tax withholding / forfeiture2.9K$124.12$360K
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCM — Option exercise5.4K$0.00
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCF — Tax withholding / forfeiture3.0K$124.12$375K
2026-02-17NBIXNEUROCRINE BIOSCIENCES INCM — Option exercise5.6K$0.00
2026-02-03NBIXNEUROCRINE BIOSCIENCES INCF — Tax withholding / forfeiture2.8K$136.06$387K
2026-02-03NBIXNEUROCRINE BIOSCIENCES INCM — Option exercise5.1K$0.00
2025-08-07NBIXNEUROCRINE BIOSCIENCES INCS — Open-market sale106.3K$126.41$13.44M
2025-08-07NBIXNEUROCRINE BIOSCIENCES INCM — Option exercise106.3K$35.99$3.83M
2025-06-12XNCRXencor IncS — Open-market sale3.2K$9.22$29K
2025-06-12XNCRXencor IncA — Grant or award13.7K$0.00
2025-05-27NBIXNEUROCRINE BIOSCIENCES INCS — Open-market sale9.6K$120.38$1.16M
2024-10-01XNCRXencor IncS — Open-market sale [10b5-1]2.7K$20.68$55K

Companies — Last 90 Days

Frequently Asked Questions

Who is GORMAN KEVIN CHARLES?

Kevin Charles Gorman is a corporate director known for his role at Neurocrine Biosciences Inc, a company focused on neurological and endocrine-related drug development. He has been involved in multiple SEC filings related to his directorship but has not reported any stock transactions.…

How many SEC Form 4 filings has GORMAN KEVIN CHARLES submitted recently?

4 primary Form 4 filings in the last 90 days, covering 2 companies.

Has GORMAN KEVIN CHARLES been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 6 open-market sales ($52.60M) across all tracked filings.

Where can I see all of GORMAN KEVIN CHARLES's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live GORMAN KEVIN CHARLES profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.